Release Date: June 03, 2021
Expiration Date: June 03, 2022
This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with congenital sucrase-isomaltase deficiency (CSID).
After completing this activity, the participants should be better able to:
Accreditation Statement and Credit Designation:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Gi Health Foundation (GiHF). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.
RMCHCS designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from
QOL, Medical LLC.
This program is not affiliated with Digestive Disease Week ®.
William Chey, MD, FACG, AGAF, FACP, RFF (Chair)
Dr. Chey received a medical degree and training in internal medicine from Emory University School of Medicine. He completed a fellowship in gastroenterology and has remained a faculty member at the University of Michigan in Ann Arbor where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology. He holds a joint appointment in the Department of Nutrition Sciences.
His research interests focus on the diagnosis and treatment of functional bowel disorders and H. pylori infection. He has mentored more than 50 students, residents, fellows and junior faculty, many of whom are leaders in gastroenterology. He is a medical innovator and holds several patents. Dr. Chey is a former co-editor-in-chief of the American Journal of Gastroenterology and has authored more than 350 manuscripts, reviews, chapters and books. Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology, Board of Directors of the Rome Foundation, and Board of Directors of the International Foundation of Functional GI Disorders.
He has been elected to "Best Doctors" since 2001 and received the Dean's Outstanding Clinician Award and Dean's Award for Innovation and Commercialization at the University of Michigan. He has also received the Distinguished Clinician Award from the American Gastroenterological Association. In 2020, he was awarded an honorary membership to the Academy of Nutrition and Dietetics and the prestigious Berk-/Fise Award from the American College of Gastroenterology.
Honorarium/Consultant: AbbVie, Allakos, Alnylam, Biomerica, IM Health, Ironwood Pharmaceuticals, Nestle, Progenity, QOL, Medical LLC, Salix Pharmaceuticals, Takeda Pharmaceuticals, Urovant, Vibrant Pharma, Inc.
Funding for Research/Researcher: NIH, Biomerica, Commonwealth Diagnostics, QOL, Medical LLC, Salix,
Vibrant Pharma, Inc.
Lin Chang, MD is a Professor of Medicine and Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine at the David Geffen School of Medicine at UCLA. She serves as the Co-Director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA. She is also Program Director of the UCLA Gastroenterology Fellowship Program. Dr. Changâ€™s clinical expertise is in disorders of gut-brain interactions (also known as functional gastrointestinal disorders). Her research focuses on pathophysiology, diagnosis and treatment of these disorders, particularly irritable bowel syndrome (IBS). She is a fellow of the American College of Gastroenterology and the American Gastroenterological Association (AGA). She has served as the Clinical Research Councilor of the AGA Governing Board. She previously served as President of the American Neurogastroenterology and Motility Society (ANMS) and is a member of the Rome Foundation Board of Directors.
Honorarium/Speaker: Arena, Ironwood, Cosmo, Shire, Takeda Pharmaceuticals.
Advisory Board: Arena, Ironwood Pharmaceuticals, Cosmo. Speaker for Non-branded Interview: Shire, Takeda Pharmaceuticals. Advisor/Stock Options: ModifyHealth. Grant Funding/Research Study: Arena, Vanda, AnX Robotica.
For the past 30 years the focus of my academic activities has been the diagnosis and treatment of functional and motility disorders in children of any age. I have pioneered the use of manometry and barostat testing to evaluate motor and sensory function in the upper and lower GI tract. I have held leadership positions within NASPGHAN, ANMS, AGA, Brain-Gut Club, and ABP. I have chaired both the Rome III and Rome IV Child-Adolescent committees and I have had more than 280 peer-reviewed and invited manuscripts in the field of functional and motility disorders in pediatrics. I was awarded the Master Award in Gastroenterology by the AGA. I was the President of NASPGHAN from 2014 to 2016.
Honorarium/Consultant: Allergan, Innovative Health Solutions, Mahana, Mallinckrodt, QOL, Medical LLC,
Prof. Satish Rao is the J. Harold Harrison, MD, Distinguished University Chair in Gastroenterology, Founding Director of the Digestive Health Center and Digestive Health Clinical Research Center, Director of Neurogastroenterology/Motility, and tenured Professor of Medicine at Augusta University, USA. He served as the Chief, of the Division of Gastroenterology/Hepatology, Director of the GI Service line, and GI Fellowship Program Director. Previously, he was Professor of Medicine and Director of Neurogastroenterology/Motility at the University of Iowa Carver College of Medicine, Iowa.
Satish Rao received his MBBS from Osmania Medical College, Hyderabad, India, his PhD from the University of Sheffield, UK; and his Fellowship of the Royal College of Physicians (FRCP) designation in the UK. He completed his internal medicine training at several centers and a clinical research fellowship at the University of Liverpool, UK. He is American Board certified in medicine and gastroenterology. He is a former president of the American Neurogastroenterology/Motility Society.
His research interests in the field of neurogastroenterology/motility have focused on gaining mechanistic insights, developing novel diagnostic tools and pioneering innovative treatments for common disorders especially constipation, dyssynergic defecation, fecal incontinence, IBS, food intolerance, gas and bloating, small intestinal bacterial and fungal overgrowth (SIBO/SIFO) and visceral pain. He is credited with discovering dyssynergic defecation, a problem that affects one-third of constipated patients and its remedy, biofeedback therapy, as well as novel treatments and sensory adaptation training for rectal hypersensitivity. He has pioneered several novel tests, translumbosacral anorectal magnetic stimulation for pelvic floor neuropathy, esophageal balloon distension for chest pain, and fructose and fructan breath tests. He developed the first method for examining bi-directional gut and brain interactions in humans. His latest invention translumbosacral neuromodulation therapy (TNT) is revolutionizing treatment for fecal incontinence. He has been awarded four patents.
Dr. Rao has been a National Institutes of Health funded principal investigator for 20 years and currently holds $ 10.6 million in NIH UO-1 grants and $3.8 million in RO-1 grants. Dr. Rao has edited 10 books, including Handbook of GI Motility (2015) and Clinical and Basic Neurogastroenterology and Motility (2020). He has published over 500 peer reviewed articles with 22,300 citations, an H index of 87, and an i10 index of 235. An astute clinician, Dr. Rao has been selected as one of the Best Doctors in America and America's Top Doctors for over 25 years. He has mentored over 100 physicians from across the world, many of whom are leaders and professors in their own countries. Thirty of his mentees have received national or international research awards, a testament to his dedication as a distinguished mentor. He has been invited to lecture in 35 countries as visiting professor. These include invitations to give live demonstrations of motility procedures and novel TNT procedures, and to train gastroenterologists and fellows globally and at multiple institutes in India and across five continents.
Dr. Satish Rao has received the three highest meritorious honors from the AGA, the AGA Distinguished Clinician Award , the AGA Masters Award for Outstanding Clinical Research and the AGA Distinguished Educator Award. He received the American College of Gastroenterology Auxiliary Research Award, the International Foundation for Functional GI Disorders Senior Clinical Investigator Award , the University of Iowa Regents Distinguished Award for Faculty Excellence, Dr. PN Chuttani Oration, the highest honor from the Indian Society of Gastroenterology , the Augusta University Distinguished Research Award and the Medical College of Georgia Distinguished Faculty Award and was named a Mexican Society Gastroenterology Honorary Diplomate/Fellow. Dr. Rao is one of a rare breed of academicians referred to as a triple threat and has excelled as an internationally renowned researcher, distinguished educator and outstanding physician.
Honorarium/Advisory Board: Ironwood Pharmaceuticals; Neurogut, Inc.; Progenity; Quin-Tron, Takeda Pharmaceuticals, Valeant Pharmaceuticals; Vibrant.
Consultant: Ironwood Pharmaceuticals, Progenity, Takeda Pharmaceuticals.
Grant Research: Progenity, Valeant Pharmaceuticals, Vibrant.
Advisory Board/Consultant/Stock: In Control Medical.